Although multiple retrospective studies have shown a correlation between urinary CXCL10 and kidney allograft rejection, the randomized controlled trial failed to demonstrate a benefit of urinary CXCL10 monitoring on one-year outcomes [12]. The gene discussed is CXCL10; the disease is medical procedure.